205 related articles for article (PubMed ID: 19214977)
1. Use of rituximab for refractory cytopenias associated with autoimmune lymphoproliferative syndrome (ALPS).
Rao VK; Price S; Perkins K; Aldridge P; Tretler J; Davis J; Dale JK; Gill F; Hartman KR; Stork LC; Gnarra DJ; Krishnamurti L; Newburger PE; Puck J; Fleisher T
Pediatr Blood Cancer; 2009 Jul; 52(7):847-52. PubMed ID: 19214977
[TBL] [Abstract][Full Text] [Related]
2. Use of mycophenolate mofetil for chronic, refractory immune cytopenias in children with autoimmune lymphoproliferative syndrome.
Rao VK; Dugan F; Dale JK; Davis J; Tretler J; Hurley JK; Fleisher T; Puck J; Straus SE
Br J Haematol; 2005 May; 129(4):534-8. PubMed ID: 15877736
[TBL] [Abstract][Full Text] [Related]
3. Effect of anti-CD20 (rituximab) on resistant thrombocytopenia in autoimmune lymphoproliferative syndrome.
Heelan BT; Tormey V; Amlot P; Payne E; Mehta A; Webster AD
Br J Haematol; 2002 Sep; 118(4):1078-81. PubMed ID: 12199788
[TBL] [Abstract][Full Text] [Related]
4. Alemtuzumab to treat refractory autoimmune hemolytic anemia or thrombocytopenia in chronic lymphocytic leukemia.
Osterborg A; Karlsson C; Lundin J
Curr Hematol Malig Rep; 2009 Jan; 4(1):47-53. PubMed ID: 20425438
[TBL] [Abstract][Full Text] [Related]
5. Rituximab for the treatment of autoimmune cytopenias in children with immune deficiency.
Kim JJ; Thrasher AJ; Jones AM; Davies EG; Cale CM
Br J Haematol; 2007 Jul; 138(1):94-6. PubMed ID: 17498197
[TBL] [Abstract][Full Text] [Related]
6. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia.
Zaja F; Iacona I; Masolini P; Russo D; Sperotto A; Prosdocimo S; Patriarca F; de Vita S; Regazzi M; Baccarani M; Fanin R
Haematologica; 2002 Feb; 87(2):189-95. PubMed ID: 11836170
[TBL] [Abstract][Full Text] [Related]
7. Rituximab for the treatment of refractory autoimmune hemolytic anemia in children.
Zecca M; Nobili B; Ramenghi U; Perrotta S; Amendola G; Rosito P; Jankovic M; Pierani P; De Stefano P; Bonora MR; Locatelli F
Blood; 2003 May; 101(10):3857-61. PubMed ID: 12531800
[TBL] [Abstract][Full Text] [Related]
8. [Primary immunodeficiencies presenting with autoimmune cytopenias in adults].
Sève P; Broussolle C; Pavic M
Rev Med Interne; 2013 Mar; 34(3):148-53. PubMed ID: 22703729
[TBL] [Abstract][Full Text] [Related]
9. Successful induction and maintenance of long-term remission in a child with chronic relapsing autoimmune hemolytic anemia using rituximab.
Gottardo NG; Baker DL; Willis FR
Pediatr Hematol Oncol; 2003; 20(7):557-61. PubMed ID: 12959862
[TBL] [Abstract][Full Text] [Related]
10. Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial.
Bride KL; Vincent T; Smith-Whitley K; Lambert MP; Bleesing JJ; Seif AE; Manno CS; Casper J; Grupp SA; Teachey DT
Blood; 2016 Jan; 127(1):17-28. PubMed ID: 26504182
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of rituximab in common variable immunodeficiency-associated immune cytopenias: a retrospective multicentre study on 33 patients.
Gobert D; Bussel JB; Cunningham-Rundles C; Galicier L; Dechartres A; Berezne A; Bonnotte B; DeRevel T; Auzary C; Jaussaud R; Larroche C; LeQuellec A; Ruivard M; Seve P; Smail A; Viallard JF; Godeau B; Hermine O; Michel M
Br J Haematol; 2011 Nov; 155(4):498-508. PubMed ID: 21981575
[TBL] [Abstract][Full Text] [Related]
12. Mycophenolate mofetil as an alternate immunosuppressor for autoimmune lymphoproliferative syndrome.
Kossiva L; Theodoridou M; Mostrou G; Vrachnou E; Le Deist F; Rieux-Laucat F; Kanariou MG
J Pediatr Hematol Oncol; 2006 Dec; 28(12):824-6. PubMed ID: 17164652
[TBL] [Abstract][Full Text] [Related]
13. Pyrimethamine treatment does not ameliorate lymphoproliferation or autoimmune disease in MRL/lpr-/- mice or in patients with autoimmune lymphoproliferative syndrome.
Rao VK; Dowdell KC; Dale JK; Dugan F; Pesnicak L; Bi LL; Hoffmann V; Penzak S; Avila NA; Fleisher TA; Puck JM; Straus SE
Am J Hematol; 2007 Dec; 82(12):1049-55. PubMed ID: 17674358
[TBL] [Abstract][Full Text] [Related]
14. Rapid regression of lymphadenopathy upon rapamycin treatment in a child with autoimmune lymphoproliferative syndrome.
Janić MD; Brasanac CD; Janković JS; Dokmanović BL; Krstovski RN; Kraguljac Kurtović JN
Pediatr Blood Cancer; 2009 Dec; 53(6):1117-9. PubMed ID: 19588524
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of rituximab in auto-immune hemolytic anemia: A meta-analysis of 21 studies.
Reynaud Q; Durieu I; Dutertre M; Ledochowski S; Durupt S; Michallet AS; Vital-Durand D; Lega JC
Autoimmun Rev; 2015 Apr; 14(4):304-13. PubMed ID: 25497766
[TBL] [Abstract][Full Text] [Related]
16. Rituximab in autoimmune hematologic diseases: not just a matter of B cells.
Stasi R
Semin Hematol; 2010 Apr; 47(2):170-9. PubMed ID: 20350664
[TBL] [Abstract][Full Text] [Related]
17. Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome.
Shanafelt TD; Madueme HL; Wolf RC; Tefferi A
Mayo Clin Proc; 2003 Nov; 78(11):1340-6. PubMed ID: 14601692
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of rituximab for systemic lupus erythematosus-associated immune cytopenias: A multicenter retrospective cohort study of 71 adults.
Serris A; Amoura Z; Canouï-Poitrine F; Terrier B; Hachulla E; Costedoat-Chalumeau N; Papo T; Lambotte O; Saadoun D; Hié M; Blanche P; Lioger B; Gottenberg JE; Godeau B; Michel M
Am J Hematol; 2018 Mar; 93(3):424-429. PubMed ID: 29247540
[TBL] [Abstract][Full Text] [Related]
19. Immune hemolytic anemia--selected topics.
Hoffman PC
Hematology Am Soc Hematol Educ Program; 2009; ():80-6. PubMed ID: 20008185
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
